Integrated system intends to accelerate enrollment by strengthening relationship between hub patient services and providers
Drug wholesaler AmerisourceBergen (ABC), and TrakCel, a software company, have launched an integrated technology platform designed to accelerate patient access to prescribed cell and gene therapies (C>s) and provide visibility throughout the treatment journey. This new offering features the combination of two platforms—OCELLOS, TrakCel’s advanced therapy orchestration platform, and Fusion, a customer relationship management and patient support ecosystem powered by ABC’s Lash Group, who specializes in patient support services.
The platform’s goal is to increase connectivity between hub patient services and providers, in order to create an exchange of benefits and eligibility information that will help expedite patient enrollment and support, ultimately helping patients start on therapies sooner. The new offering adds to ABC’s portfolio of services that work to meet the needs of the C> sector—from pre-clinical and commercial logistics, to market access and reimbursement consulting and patient support services.
“ … By combining the capabilities of Fusion and OCELLOS, we’re streamlining the path to care, improving speed-to-therapy and creating a heightened level of connectivity across the supply chain,” says Willis Chandler, ABC’s president of manufacturer services and commercial solutions at AmerisourceBergen. “This represents an important step in AmerisourceBergen’s ongoing commitment to build an end-to-end service offering that supports innovators in enhancing patient access to these critical therapies.”